Skip to main content
Evidence Snapshot

Mu-type opioid receptor

CHEMBL4354 SINGLE PROTEIN Cavia porcellus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:26Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4354
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Mu-type opioid receptor as ChEMBL target CHEMBL4354, mapped to UniProt P97266. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Mu-type opioid receptor
SINGLE PROTEIN · Cavia porcellus
As of 2026-09-13
ChEMBL target ID
CHEMBL4354
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P97266
Mu-type opioid receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Mu-type opioid receptor matters

As of 2026-09-13

Mu-type opioid receptor is reviewed as Mu-type opioid receptor (UniProt P97266); the current evidence base includes 21 approved drugs, 2376 compounds, and 692 assays, with lead potency reaching pChEMBL 11.0.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 21 approved drugs, 2376 compounds, and 692 assays for this target. The dominant activity type is IC50. CHEMBL2113675 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL2113675 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
21 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Mu-type opioid receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P97266, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2376
Total Compounds
692
Total Assays
21
Approved Drugs
IC50: 1291.0, KI: 1051.0, EC50: 68.0, KD: 59.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL2113675
11.0 Ki
10.9 Ki
No preferred name
CHEMBL290429
10.7 IC50 Clinical
No preferred name
CHEMBL300662
10.7 Ki
10.6 Ki

Approved Drugs

Structure Compound First Approval
NALFURAFINE
CHEMBL267495
2009
2009
LEVORPHANOL
CHEMBL592
1991
ALFENTANIL
CHEMBL634
1986
NALTREXONE
CHEMBL19019
1984
MORPHINE
CHEMBL70
1984
BUPRENORPHINE
CHEMBL511142
1981
LOPERAMIDE
CHEMBL841
1976
NALOXONE
CHEMBL80
1971
1968
FENTANYL
CHEMBL596
1968
OXYMORPHONE
CHEMBL963
1959
MEPERIDINE
CHEMBL607
1942
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:26Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4354